310 related articles for article (PubMed ID: 33409252)
21. BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS/FTD model.
Quezada E; Cappelli C; Diaz I; Jury N; Wightman N; Brown RH; Montecino M; van Zundert B
Clin Epigenetics; 2021 Mar; 13(1):56. PubMed ID: 33726839
[TBL] [Abstract][Full Text] [Related]
22. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.
Morgado-Pascual JL; Rayego-Mateos S; Tejedor L; Suarez-Alvarez B; Ruiz-Ortega M
Front Pharmacol; 2019; 10():1315. PubMed ID: 31780938
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the acetyl lysine-binding pocket of bromodomain and extraterminal domain proteins interferes with adipogenesis.
Goupille O; Penglong T; Kadri Z; Granger-Locatelli M; Fucharoen S; Maouche-Chrétien L; Prost S; Leboulch P; Chrétien S
Biochem Biophys Res Commun; 2016 Apr; 472(4):624-30. PubMed ID: 26972250
[TBL] [Abstract][Full Text] [Related]
24. Functional coupling between writers, erasers and readers of histone and DNA methylation.
Torres IO; Fujimori DG
Curr Opin Struct Biol; 2015 Dec; 35():68-75. PubMed ID: 26496625
[TBL] [Abstract][Full Text] [Related]
25. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
26. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
27. Selective targeting of epigenetic reader domains.
Greschik H; Schüle R; Günther T
Expert Opin Drug Discov; 2017 May; 12(5):449-463. PubMed ID: 28277835
[TBL] [Abstract][Full Text] [Related]
28. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
29. Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.
Järvenpää J; Rahnasto-Rilla M; Lahtela-Kakkonen M; Küblbeck J
Biomed Pharmacother; 2022 Mar; 147():112652. PubMed ID: 35065514
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
31. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
32. Role of bromodomain and extraterminal (BET) proteins in prostate cancer.
Mandl A; Markowski MC; Carducci MA; Antonarakis ES
Expert Opin Investig Drugs; 2023 Mar; 32(3):213-228. PubMed ID: 36857796
[TBL] [Abstract][Full Text] [Related]
33. BET bromodomains as novel epigenetic targets for brain health and disease.
Singh MB; Sartor GC
Neuropharmacology; 2020 Dec; 181():108306. PubMed ID: 32946883
[TBL] [Abstract][Full Text] [Related]
34. Current Status of Epigenetics and Anticancer Drug Discovery.
Jin P; Chen X
Anticancer Agents Med Chem; 2016; 16(6):699-712. PubMed ID: 26567620
[TBL] [Abstract][Full Text] [Related]
35. Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.
Bauer K; Berghoff AS; Preusser M; Heller G; Zielinski CC; Valent P; Grunt TW
Am J Cancer Res; 2021; 11(2):530-545. PubMed ID: 33575085
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of epigenetic "readers, writers and erasers": Implications for developmental reprogramming and the epigenetic basis for health and disease.
Treviño LS; Wang Q; Walker CL
Prog Biophys Mol Biol; 2015 Jul; 118(1-2):8-13. PubMed ID: 25841987
[TBL] [Abstract][Full Text] [Related]
37. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
38. Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury.
Rudman MD; Choi JS; Lee HE; Tan SK; Ayad NG; Lee JK
Exp Neurol; 2018 Nov; 309():181-192. PubMed ID: 30134146
[TBL] [Abstract][Full Text] [Related]
39. Photoreceptor protection via blockade of BET epigenetic readers in a murine model of inherited retinal degeneration.
Zhao L; Li J; Fu Y; Zhang M; Wang B; Ouellette J; Shahi PK; Pattnaik BR; Watters JJ; Wong WT; Guo LW
J Neuroinflammation; 2017 Jan; 14(1):14. PubMed ID: 28103888
[TBL] [Abstract][Full Text] [Related]
40. Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment.
Mio C; Bulotta S; Russo D; Damante G
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30634442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
